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Abstract
Purpose: To determine whether performing adrenalectomy at the time of nephrectomy for unilateral
Wilms tumor impacts clinical outcome.
Methods: We reviewed information on all patients enrolled on National Wilms Tumor Study-4 and -5.
Data were abstracted on patient demographics, tumor characteristics, surgical and pathologic status of
the adrenal gland, and patient outcomes. The primary endpoints were intraoperative spill and five-year
event-free survival (EFS) in patients who did or did not undergo adrenalectomy.
Results: Of 3825 patients with complete evaluable data, the adrenal was left in situ in 2264 (57.9%) patients,
and was removed completely in 1367 patients (36.7%) or partially in 194 patients (5.2%). Of the adrenal
glands removed, 68 (4.4%) contained tumor. Adrenal involvement was more common in patients with stage
3 (9.8%) than stage 2 disease (1.9%; p b 0.0001). After controlling for stage and histopathology, five-year
EFS was similar whether or not the adrenal gland was removed (p = 0.48), or involved with tumor
(p = 0.81); however, intraoperative spill rates were higher in patients undergoing adrenalectomy (26.1% vs
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15.5%, p b 0.0001), likely due to larger tumor size or technical factors. No patient had clinical evidence of
adrenal insufficiency or tumor recurrence in the adrenal gland during follow-up (median 9.9 years).
Conclusions: Sparing the adrenal gland during nephrectomy for unilateral Wilms tumor was not associated
with a higher incidence of intraoperative spill and was associated with a similar oncologic outcome, on a perstage basis, with cases where the adrenal was removed. Thus, adrenalectomy should not be considered
mandatory during radical nephrectomy for Wilms tumor.
© 2013 Elsevier Inc. All rights reserved.

The National Wilms Tumor Study Group (NWTSG)
conducted a series of multi-institutional clinical trials,
beginning in 1969, which have identified prognostic factors
and optimized treatment regimens for patients with Wilms
tumor [1]. Based on this experience, the current standard of
care for patients with localized Wilms tumor in North
America is upfront unilateral nephrectomy with lymph node
sampling. Histopathologic subtype and pathologic stage of
the tumor determine the need for, and duration and intensity
of, adjuvant chemotherapy and radiation therapy [2,3].
While it is generally accepted that the primary surgical
objective in patients with localized Wilms tumor is complete
resection of the neoplasm without spill, extensive resection
of adjacent viscera to achieve a complete resection is
discouraged because of the sensitivity of Wilms tumor to
adjuvant therapy. However, although a classic radical
nephrectomy includes resection of the ipsilateral adrenal
gland [4], there are currently no specific recommendations
regarding adrenalectomy in patients with clinically localized
Wilms tumor; the management of the adrenal gland has
typically been left to the discretion of the operating surgeon.
There is also a dearth of literature on the incidence of adrenal
involvement in patients with Wilms tumor; two published
series report adrenal involvement in fewer than 2% of
patients [5,6]. In addition, no studies have specifically
addressed differential spill and survival rates based on
whether or not the adrenal gland was removed as part of a
radical nephrectomy in patients with unilateral Wilms tumor.
Although patients with adrenal involvement can still be
classified as stage 2 if all disease is resected with negative
margins [7], (and therefore receive only two-drug chemotherapy following nephrectomy), the need to perform
adrenalectomy when the adrenal appears to be uninvolved
with tumor is unclear and may be driven more by the desire
to avoid tumor rupture.
Conversely, adrenal insufficiency has very rarely been
described following unilateral adrenal resection for either
primary adrenal disease or as part of radical nephrectomy
[8-10] and has never been observed in the NWTS
experience. Nevertheless, this condition can be life-threatening in its acute manifestation and, when chronic, mandates
lifelong mineralocorticoid and glucocorticoid replacement,
with the attendant side effects of these medications.
Furthermore, metachronous contralateral tumors are seen in
approximately 1% of patients with unilateral Wilms tumor
[11], and patients in whom the ipsilateral adrenal gland was
removed as a matter of course during resection of the primary

tumor may have fewer options for management of the
recurrent disease without inducing adrenal insufficiency.
Given the need to balance oncologic control and the
potentially deleterious side effects of adrenalectomy, we
undertook this study to formally assess the impact of
adrenalectomy on clinical outcomes. The goal of this study
was to determine the prognostic impact of adrenalectomy in
patients treated on NWTS-4 and -5; specifically, whether
adrenalectomy was associated with variations in event-free
survival (EFS) or intraoperative spill rates in patients with
unilateral, localized Wilms tumor.

1. Methods
After obtaining Institutional Review Board approval, the
records of 3913 patients were reviewed; all were enrolled in
the NWTS-4 and -5 studies and had undergone unilateral
nephrectomy for non-metastatic Wilms tumor. Enrollment
for NWTS-4 and -5 was ongoing between August 1986 and
May 2002. Since therapy for unilateral, nonmetastatic Wilms
tumor was similar in NTWS-4 and -5, with the primary
difference being duration of therapy for favorable histology
disease, the results from these two studies were combined for
analysis. Patients who received pre-nephrectomy chemotherapy or who underwent partial nephrectomy for bilateral
(or unilateral) disease, as well as those with evidence of
metastatic disease were excluded. Patients with a diagnosis
of clear cell sarcoma of the kidney, rhabdoid tumor of the
kidney, or renal cell carcinoma were also excluded.
Data collected included patient demographics, tumor
histopathology, surgical status of the adrenal gland (e.g.
removed, preserved, or partially removed), the presence or
absence of tumor in the adrenal gland, margin status, tumor
weight, presence and extent of intraoperative spill, and
pathologic stage. All histopathologic data were abstracted
from the central pathology report except when slides of
resected adrenal tissue were not sent for central review; in
these few patients, the institutional assessment of adrenal
involvement was recorded.
Event-free survival (EFS) was defined as the time from
study entry until the first occurrence of disease progression,
relapse after response, or death as a first event from any cause.
Follow-up for patients not experiencing an event was censored
at the time of last follow-up. Kaplan–Meier curves were
calculated to estimate five-year EFS for various patient subsets.
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Table 1
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Surgical management of the adrenal gland, stratified by disease stage.

Adrenal Status

Stage
1

2

3

Left In Situ
Partially Removed
Completely Removed

1016 (72%)
54 (4%)
347 (24%)

736 (55%)
76 (6%)
515 (39%)

512 (47%)
64 (6%)
505 (47%)

The EFS among patient subsets was compared using the logrank test. Cumulative incidence rates of tumor bed recurrences
were estimated treating all other failure types as competing
risks. The independent contribution of various factors to the
prediction of EFS was assessed using the Cox proportional
hazards model. Differences were considered statistically
significant if p b 0.05. Analyses were performed using
commercially available statistical software (SAS, Cary, NC).

2. Results
The records of 3913 patients were reviewed. Eighty-eight
(2.2%) cases were excluded from the analysis because details
about either the surgical or pathologic status of the adrenal
gland, or data on disease stage were unavailable. For the
remaining 3825 patients, the adrenal gland was completely
resected in 1367 (35.7%) patients and preserved in 2264
(59.2%) patients. In the remaining 194 (5.1%) patients, the
adrenal gland was partially removed en bloc with the
nephrectomy specimen, with the surgeon specifically noting
the intent to preserve a portion of the gland. Adjuvant
therapy based on tumor stage and histology was administered per the contemporary COG protocols, including flank
radiation for positive surgical margins or tumor spill.
Adrenal involvement per se did not alter therapy. Patients
in whom the adrenal was involved but completely resected
en bloc were considered stage II. Patients with involvement
at the resection margin were considered stage III and
received 3 drugs and flank RT.

Fig. 1

In patients in whom the adrenal was at least partially
removed, the histology of the primary tumor was favorable in
1446 (92.6%) cases, focal anaplasia in 20 (1.3%) cases, and
diffuse anaplasia in 95 (6.1%) cases. In patients in whom the
adrenal was preserved, the histology of the primary tumor
was favorable in 2099 (92.7%) cases, focal anaplasia in 39
(1.7%) cases, and diffuse anaplasia in 126 (5.6%) cases.
Thus, overall, tumor histopathology was similar in patients in
whom the adrenal was removed and those in whom it was
preserved (p = 0.45). Tumors in which the adrenal gland was
partially (664 ± 423 g) or completely (671 ± 382 g) removed were larger than those in which the adrenal gland was
left in situ (524 ± 378 g; p b 0.0001). Table 1 describes the
surgical management of the adrenal gland, stratified by the
pathologic stage of disease; adrenalectomy was more
common in patients with higher stage disease (p b 0.0001).
Five-year EFS was similar in patients in whom the adrenal
gland was partially (84%) or entirely (86%) removed
compared with patients in whom the adrenal gland was left
in situ (87%, p = 0.23; Fig. 1), even after adjusting for stage
and histopathology (p = 0.48). The intraoperative spill rate
was 26.1% (408/1561) in patients in whom the adrenal was
removed compared with 15.5% (351/2264; p b 0.0001) in
patients in whom the gland was preserved. Sixty-eight
(4.4%) of the 1561 patients in whom the adrenal was
evaluated had direct tumor extension or metastases into the
adrenal gland or periadrenal fat. Of these 68 patients, 26
(38.2%) had gross involvement of the adrenal gland (23 by
direct invasion and three with discrete metastatic disease), 35
(51.4%) had microscopic invasion only, and 7 (10.2%) had

Five-year EFS in all patients, stratified by surgical status of the adrenal gland (p = 0.23).
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compared with patients with focal (10%) or diffuse (7.4%)
anaplasia (p = 0.10). Clinical evidence of acute or chronic
adrenal insufficiency following adrenalectomy was not
reported in any patient in our series; however, patients were
not routinely tested for subclinical adrenal insufficiency.

3. Discussion

Fig. 2 Adrenal involvement with tumor, stratified by pathologic
stage (p b 0.0001).

involvement of the periadrenal fat only. Adrenal involvement was similar whether the tumor was located in the left
(4.5%) or right (3.8%) kidney (p = 0.60), but was more
common in patients with higher stage disease (p b 0.0001;
Fig. 2). After controlling for stage and histopathology, fiveyear EFS in patients with adrenal involvement was 82%
compared to 85% for patients without adrenal gland
involvement and 87% for patients in whom the adrenal
was not evaluated (p = 0.81; Fig. 3).
Of 551 patients with recurrent disease, 96 (17.4%) had
recurrence in the initial operative bed. Thirty-eight (39.6%) of
these patients had adrenal tissue available for analysis, of
whom only one (2.6%) had adrenal involvement at the time of
initial surgery. Five-year cumulative recurrence rates in the
operative bed were similar in patients in whom the adrenal
was entirely (2.1%), partially (3.1%), or not (3.5%) removed
(p = 0.53). No patient was recorded as having a recurrence
within the adrenal gland itself. Patients with favorable
histology had similar rates of adrenal involvement (4.1%)

Fig. 3

There are no specific, evidence-based recommendations
in current COG protocols on how to manage the ipsilateral
adrenal gland when performing a nephrectomy for unilateral
Wilms tumor. Thus, the decision is left to the operating
surgeon and is probably based on a variety of considerations
including the desire to avoid tumor rupture and remove all
disease while sparing uninvolved organs, including the
adrenal gland. In this study, five-year event-free survival did
not differ whether or not concurrent adrenalectomy was
performed at the time of nephrectomy, suggesting that
routine adrenalectomy does not confer a benefit for
oncologic control when it is feasible to spare the adrenal
gland. Whether or not adrenalectomy was performed,
oncologic outcome remained similar even after controlling
for disease histology and stage. Although the oncologic
status of the adrenal glands left in situ cannot be known, our
data suggest that even if some glands harbored microscopic
tumor, there is no benefit to the surgical management of
micrometastatic adrenal disease. Our findings are similar to
those in a smaller Canadian series which found only four
(6.9%) of 58 excised adrenal glands had tumor within the
gland itself or within the periadrenal fat, and that tumor
spillage rates were higher (though not significantly so) in
patients undergoing adrenalectomy [6].
In renal cell carcinoma, risk factors for adrenal
involvement can be identified preoperatively [12,13], and
in patients without clinical or radiographic evidence of
adrenal disease, routine adrenalectomy did not improve

Five-year EFS in all patients, stratified by pathologic status of the adrenal gland (p = 0.81).
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oncologic outcome [13–16]. Since adrenal involvement is
much less common and adjuvant therapy much more
effective in Wilms tumor than renal cell carcinoma, this
further underscores our finding that the risks of routine
adrenalectomy in patients with Wilms tumor likely
outweigh the potential benefits.
Intraoperative tumor spill rates were actually higher in
patients in whom adrenalectomy was performed. While a
full analysis of tumor spill and risk factors is not the focus
of this paper, it is likely that characteristics of the tumor
which would render tumor resection more technically
challenging and might independently increase spill risk
(e.g. size, proximity to other structures, friability) would
influence the decision of the surgeon to resect or attempt to
preserve the adrenal gland at the time of nephrectomy. This
is supported by our finding that patients in whom
adrenalectomy was performed tended to have larger tumors
than those in whom the gland was left in situ. We do not
believe that the technical performance of adrenalectomy
contributed to the higher rate of tumor spill. Prior studies
have suggested that tumor size (larger than 10 cm diameter)
is the main factor that affects tumor spill. Tumor diameter
and other tumor characteristics, such as location within the
kidney, were not routinely recorded in all patients, making
it difficult to control for these factors and more precisely
define the independent impact of adrenalectomy on tumor
spill [17].
Interestingly, we did not find that the five-year EFS was
worse in patients in whom there was adrenal involvement
with tumor, compared to those patients who had no adrenal
involvement or those in whom the adrenal was not sampled.
This suggests that the histopathologic status of the adrenal
gland does not directly affect oncologic outcome; patients in
whom the adrenal was removed may have had a more
technically challenging surgery, with the need to perform a
wide resection inclusive of the adrenal gland being a marker
for complex tumor or patient characteristics which may
independently increase the risk of spill. Since a large
proportion of patients with adrenal involvement had
microscopic disease, it is possible that some patients in
whom the adrenal was left in situ also had microscopic
metastatic disease which was effectively treated by chemotherapy, and thus, may not be clinically relevant.
The rate of adrenal involvement in our series was minimal
(1.2%) in patients with completely resected (Stage 1 or 2)
disease, compared with 10% in patients with Stage 3 disease;
the similar clinical outcomes in these groups likely reflect the
high sensitivity of Wilms tumor to chemotherapeutic agents
and radiotherapy. Since only a small number of patients with
focal and diffuse anaplasia had adrenal involvement, fiveyear EFS was not stratified by histopathologic subtype; again,
however, differential survival rates with adrenal involvement
in patients with diffuse anaplasia compared with those with
favorable or focal anaplastic histology would likely support a
role for both tumor histopathology and chemotherapy as
mitigating factors in the prognosis of adrenal involvement.
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However, the limited number of patients with anaplasia in our
series precludes a formal analysis.
Previous reports from the National Wilms Tumor Study
have found an important role for intraoperative decision
making in the surgical management of Wilms tumor [18-20].
Thus, our finding that adrenalectomy rates rose in parallel
with increasing clinical stage is not surprising, given that
surgeons would likely seek to achieve a more extensive
resection in patients in whom intraoperative findings
suggested more extensive disease to avoid tumor rupture.
However, our study design does not permit us to retrospectively assess a surgeon’s rationale for removing the adrenal
gland; in some cases, preservation may have been made
technically challenging by the location and size of the
primary tumor, whereas adrenal involvement may have been
suspected in other patients based on visual or palpable
findings evident only at the time of surgery. We are also
unable to assess whether there was unequivocal radiographic
evidence for or against adrenal involvement on preoperative
imaging; the original cross-sectional imaging was not
available for review, and only a small minority of radiology
reports specifically addressed the intrarenal location of the
tumor or the radiographic status of the adrenal gland.
Unquantifiable intraoperative variables may also explain
why the five-year EFS rate is higher in patients in whom the
adrenal was not assessed compared to those in whom the
adrenal was removed (regardless of the gland’s oncologic
status); it is possible that patients in whom the location and
size of the primary tumor favored adrenal preservation fared
better than those in whom the adrenal was resected, based on
factors related to the primary tumor rather than the adrenal
gland itself.
Currently, the decision to remove the adrenal or leave the
gland in situ is made by the surgeon at the time of nephrectomy,
and is likely based on the size and location of the primary tumor,
ease of adrenalectomy, and suspicion for adrenal involvement,
among other factors. Based on the low rate of adrenal
involvement, and lack of apparent oncologic benefit to
adrenalectomy concurrent with nephrectomy seen in our
study, routine adrenalectomy does not appear to be mandatory.
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